NCT02078141View on ClinicalTrials.gov

18F-deoxyglucose (FDG) PET-CMD

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 24, 2014

Primary Completion Date

January 18, 2018

Study Completion Date

January 18, 2018

Conditions
Patients With Idiopathic Dilated Cardiomyopathy
Interventions
DRUG

18F-deoxyglucose (FDG)

18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq

Trial Locations (2)

44805

West Cancerology Institute/Nantes UH : PET plateform, Saint-Herblain

44903

Nantes UH, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT02078141 - 18F-deoxyglucose (FDG) PET-CMD | Biotech Hunter | Biotech Hunter